Scholarlink

Summary <p>Older adults often face rapid loss of bone and muscle after a hip fracture, which can hinder recovery and independence. Anabolic steroid therapy increased bone mineral density and enhanced functional performance without notable side effects, showing potential as an adjunct to rehabilitation to support musculoskeletal recovery in postoperative elderly patients.</p> Introduction <p>Proximal femur (“hip”) fractures are associated with high complication rates and challenging rehabilitation courses in the geriatric population. These patients can develop rapid sarcopenia and bone loss. Anabolic agents such as androgenic anabolic steroids (AAS) might&#xa0;counteract this catabolic state, but their efficacy remains uncertain. The purpose of this systematic review and meta-analysis was to evaluate whether postoperative AAS improves the outcomes in geriatric hip fractures.</p> Methods <p>A systematic search of MEDLINE, Embase, CENTRAL, Web of Science, Google Scholar, ClinicalTrials.gov, and Wiley (inception to June 1, 2025) identified randomized controlled trials (RCTs) comparing an AAS with placebo/standard care after hip fracture. After record screening and data extraction, the data from studies evaluating AAS were analyzed using fixed-effect modeling. In addition, studies were assessed descriptively. The certainty of evidence was graded using the GRADE system.</p> Results <p>Nine RCTs (466 total participants; 214 received anabolic agents) met the inclusion criteria. AAS therapy significantly increased hip bone mineral density (BMD) z-score (d = 1.29, 95% CI 1.04–1.55; moderate certainty). The Harris Hip Score (HHS) (d = 2.85, 95% CI 2.52–3.17) and Katz Activities of Daily Living (KADL) index (d = 0.95, 95% CI 0.71–1.19) also improved with anabolic therapy. HHS and KADL index findings had very low certainty due to a high risk of bias and imprecision. No significant gain was observed in operative-leg strength versus the contralateral leg. Thirteen mild, transient adverse events (liver-enzyme elevation, sweating, hirsutism) occurred among AAS patients (13/214, 6.1%). No serious androgen-related complications were reported.</p> Conclusion <p>Low-dose AAS after hip fracture surgery increased BMD and improved patient-reported function without significant safety concerns. Still, evidence of functional benefits is limited by small, often unblinded trials. Larger, multicenter RCTs using standardized treatment protocols and functional endpoints will help better determine the benefits of AAS after proximal femur fractures.</p> Level of Evidence <p>Level I, Systematic Review and Meta-analysis</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anabolic‐steroid therapy after geriatric proximal femur fracture: a level I evidence systematic review and meta-analysis of bone density, functional recovery, and safety

  • 期刊论文

  • 发表日期：

    2025年11月17日

查看全文
  • McKenna W. Box,
  • Kyle P. O’Connor,
  • Josh Major,
  • Troy B. Puga,
  • Winston Scambler,
  • John T. Riehl

摘要

Summary

Older adults often face rapid loss of bone and muscle after a hip fracture, which can hinder recovery and independence. Anabolic steroid therapy increased bone mineral density and enhanced functional performance without notable side effects, showing potential as an adjunct to rehabilitation to support musculoskeletal recovery in postoperative elderly patients.

Introduction

Proximal femur (“hip”) fractures are associated with high complication rates and challenging rehabilitation courses in the geriatric population. These patients can develop rapid sarcopenia and bone loss. Anabolic agents such as androgenic anabolic steroids (AAS) might counteract this catabolic state, but their efficacy remains uncertain. The purpose of this systematic review and meta-analysis was to evaluate whether postoperative AAS improves the outcomes in geriatric hip fractures.

Methods

A systematic search of MEDLINE, Embase, CENTRAL, Web of Science, Google Scholar, ClinicalTrials.gov, and Wiley (inception to June 1, 2025) identified randomized controlled trials (RCTs) comparing an AAS with placebo/standard care after hip fracture. After record screening and data extraction, the data from studies evaluating AAS were analyzed using fixed-effect modeling. In addition, studies were assessed descriptively. The certainty of evidence was graded using the GRADE system.

Results

Nine RCTs (466 total participants; 214 received anabolic agents) met the inclusion criteria. AAS therapy significantly increased hip bone mineral density (BMD) z-score (d = 1.29, 95% CI 1.04–1.55; moderate certainty). The Harris Hip Score (HHS) (d = 2.85, 95% CI 2.52–3.17) and Katz Activities of Daily Living (KADL) index (d = 0.95, 95% CI 0.71–1.19) also improved with anabolic therapy. HHS and KADL index findings had very low certainty due to a high risk of bias and imprecision. No significant gain was observed in operative-leg strength versus the contralateral leg. Thirteen mild, transient adverse events (liver-enzyme elevation, sweating, hirsutism) occurred among AAS patients (13/214, 6.1%). No serious androgen-related complications were reported.

Conclusion

Low-dose AAS after hip fracture surgery increased BMD and improved patient-reported function without significant safety concerns. Still, evidence of functional benefits is limited by small, often unblinded trials. Larger, multicenter RCTs using standardized treatment protocols and functional endpoints will help better determine the benefits of AAS after proximal femur fractures.

Level of Evidence

Level I, Systematic Review and Meta-analysis